SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-011473
Filing Date
2022-06-10
Accepted
2022-06-10 16:06:01
Documents
13
Period of Report
2022-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20220610.htm   iXBRL 8-K 82189
2 EX-4.1 inzy-ex4_1.htm EX-4.1 124252
  Complete submission text file 0000950170-22-011473.txt   357482

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20220610_pre.xml EX-101.PRE 11500
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20220610.xsd EX-101.SCH 2471
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20220610_lab.xml EX-101.LAB 18519
7 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20220610_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 221008869
SIC: 2834 Pharmaceutical Preparations